Industry Program

Synopsis: In this symposia, presenters will review the latest evidence informing the use of Upadacitinib in rheumatologic conditions in the context of today’s treatment landscape

Synopsis: The planned medac breakfast symposium “Improving conventional therapy for patients with rheumatoid arthritis by subcutaneous MTX” will elaborate on the therapeutic strategies in the

Synopsis: The purpose of this symposium is to outline the paradigm shift in understanding the pathophysiology and new treatments strategy in SLE/Lupus. Agenda: Chairperson: Prof.

Synopsis: Information coming soon Food inclusions: TBA Agenda: Chairperson: Prof Yuko Kaneko TBA mins Welcome Remarks: Introduction TBA mins The utility of the collaboration of

Ozoralizumab as a Novel Therapeutic Option for Rheumatoid Arthritis in a Super-Aged Society

Synopsis: Information coming soon Food inclusions: TBA Agenda: Chairperson: Dr. Kunihiro Yamaoka TBA mins Welcome Remarks: Introduction TBA mins Frontiers in (of) targeted therapy (therapies) on

Synopsis: Information coming soon Food inclusions: TBA Agenda: Chairperson/s: Prof. Hoon-Suk Cha and Prof. Kunihiro Yamaoka TBA mins Welcome Remarks: Introduction TBA mins Presentation title

Synopsis: Information coming soon Food inclusions: TBA Agenda: Chairperson: Roger Levy TBA mins Introduction – SLE/LN in Asia : our current challenges Prof. Yoshiya Tanaka

Synopsis: It is 15 years since the first Treat-to-Target recommendations in rheumatoid arthritis (RA) were published. In 2025, this treatment strategy for the management of

Synopsis: Information coming soon Food inclusions: TBA Agenda: TBA mins Welcome Remarks: Introduction TBA mins Presentation title TBA Speaker TBA TBA mins Presentation title TBA